iShares U.S. Pharmaceuticals ETF (AMEX: IHE) Stock Competitors & Peer Comparison

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VSMPX has a market cap of 2.3T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VSMPX trades at $345.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VSMPX's P/E ratio is 26.81. In terms of profitability, IHE's ROE is +0.00%, compared to VSMPX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VSMPX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VSMPX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTSAX has a market cap of 2.3T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTSAX trades at $184.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTSAX's P/E ratio is 26.81. In terms of profitability, IHE's ROE is +0.00%, compared to VTSAX's ROE of +0.08%. Regarding short-term risk, IHE is more volatile compared to VTSAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTSAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VITSX has a market cap of 2.3T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VITSX trades at $184.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VITSX's P/E ratio is -1527.25. In terms of profitability, IHE's ROE is +0.00%, compared to VITSX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VITSX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VITSX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, PMFLX has a market cap of 1.9T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while PMFLX trades at $9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas PMFLX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to PMFLX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to PMFLX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check PMFLX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VOO has a market cap of 1.7T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VOO trades at $703.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VOO's P/E ratio is 27.47. In terms of profitability, IHE's ROE is +0.00%, compared to VOO's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to VOO. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VOO's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VFFSX has a market cap of 1.7T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VFFSX trades at $376.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VFFSX's P/E ratio is 27.34. In terms of profitability, IHE's ROE is +0.00%, compared to VFFSX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VFFSX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VFFSX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VFIAX has a market cap of 1.7T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VFIAX trades at $709.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VFIAX's P/E ratio is 27.34. In terms of profitability, IHE's ROE is +0.00%, compared to VFIAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VFIAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VFIAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VFINX has a market cap of 1.7T. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VFINX trades at $709.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VFINX's P/E ratio is 27.35. In terms of profitability, IHE's ROE is +0.00%, compared to VFINX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VFINX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VFINX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FXAIX has a market cap of 832.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FXAIX trades at $267.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FXAIX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to FXAIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FXAIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FXAIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, SPY has a market cap of 815.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while SPY trades at $765.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas SPY's P/E ratio is 25.94. In terms of profitability, IHE's ROE is +0.00%, compared to SPY's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to SPY. This indicates higher risk in terms of short-term price fluctuations for IHE.Check SPY's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTIAX has a market cap of 666.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTIAX trades at $47.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTIAX's P/E ratio is 18.20. In terms of profitability, IHE's ROE is +0.00%, compared to VTIAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VTIAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTIAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTPSX has a market cap of 666.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTPSX trades at $188.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTPSX's P/E ratio is 18.19. In terms of profitability, IHE's ROE is +0.00%, compared to VTPSX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VTPSX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTPSX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTSNX has a market cap of 662.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTSNX trades at $188.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTSNX's P/E ratio is 18.19. In terms of profitability, IHE's ROE is +0.00%, compared to VTSNX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VTSNX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTSNX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, QQQ has a market cap of 508.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while QQQ trades at $713.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas QQQ's P/E ratio is 32.76. In terms of profitability, IHE's ROE is +0.00%, compared to QQQ's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to QQQ. This indicates higher risk in terms of short-term price fluctuations for IHE.Check QQQ's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, BMOP has a market cap of 434B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while BMOP trades at $24.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas BMOP's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to BMOP's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to BMOP. This indicates higher risk in terms of short-term price fluctuations for IHE.Check BMOP's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VBMFX has a market cap of 399.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VBMFX trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VBMFX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to VBMFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VBMFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VBMFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VUG has a market cap of 389.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VUG trades at $87.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VUG's P/E ratio is 33.77. In terms of profitability, IHE's ROE is +0.00%, compared to VUG's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to VUG. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VUG's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VIGAX has a market cap of 387.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VIGAX trades at $270.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VIGAX's P/E ratio is 33.63. In terms of profitability, IHE's ROE is +0.00%, compared to VIGAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VIGAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VIGAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VIGIX has a market cap of 387.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VIGIX trades at $270.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VIGIX's P/E ratio is 33.63. In terms of profitability, IHE's ROE is +0.00%, compared to VIGIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VIGIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VIGIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, CGFAX has a market cap of 369.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while CGFAX trades at $86.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas CGFAX's P/E ratio is 33.36. In terms of profitability, IHE's ROE is +0.00%, compared to CGFAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to CGFAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check CGFAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, GFFFX has a market cap of 366.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while GFFFX trades at $87.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas GFFFX's P/E ratio is 32.35. In terms of profitability, IHE's ROE is +0.00%, compared to GFFFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to GFFFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check GFFFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, GFAFX has a market cap of 366.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while GFAFX trades at $87.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas GFAFX's P/E ratio is 33.12. In terms of profitability, IHE's ROE is +0.00%, compared to GFAFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to GFAFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check GFAFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VIIIX has a market cap of 357.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VIIIX trades at $615.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VIIIX's P/E ratio is 27.34. In terms of profitability, IHE's ROE is +0.00%, compared to VIIIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VIIIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VIIIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VINIX has a market cap of 357.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VINIX trades at $615.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VINIX's P/E ratio is 27.34. In terms of profitability, IHE's ROE is +0.00%, compared to VINIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VINIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VINIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, GAFFX has a market cap of 353.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while GAFFX trades at $88.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas GAFFX's P/E ratio is 33.17. In terms of profitability, IHE's ROE is +0.00%, compared to GAFFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to GAFFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check GAFFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RGAGX has a market cap of 353.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RGAGX trades at $88.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RGAGX's P/E ratio is 33.17. In terms of profitability, IHE's ROE is +0.00%, compared to RGAGX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RGAGX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RGAGX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AGTHX has a market cap of 353.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AGTHX trades at $88.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AGTHX's P/E ratio is 33.13. In terms of profitability, IHE's ROE is +0.00%, compared to AGTHX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AGTHX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AGTHX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VEA has a market cap of 328.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VEA trades at $73.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VEA's P/E ratio is 18.93. In terms of profitability, IHE's ROE is +0.00%, compared to VEA's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to VEA. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VEA's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTMGX has a market cap of 324.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTMGX trades at $23.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTMGX's P/E ratio is 18.73. In terms of profitability, IHE's ROE is +0.00%, compared to VTMGX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VTMGX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTMGX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VDIPX has a market cap of 324.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VDIPX trades at $36.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VDIPX's P/E ratio is 18.73. In terms of profitability, IHE's ROE is +0.00%, compared to VDIPX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VDIPX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VDIPX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTMNX has a market cap of 322.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTMNX trades at $23.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTMNX's P/E ratio is 18.73. In terms of profitability, IHE's ROE is +0.00%, compared to VTMNX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VTMNX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTMNX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, BALFX has a market cap of 291.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while BALFX trades at $41.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas BALFX's P/E ratio is 26.59. In terms of profitability, IHE's ROE is +0.00%, compared to BALFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to BALFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check BALFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AFMBX has a market cap of 291.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AFMBX trades at $41.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AFMBX's P/E ratio is 26.60. In terms of profitability, IHE's ROE is +0.00%, compared to AFMBX's ROE of +0.13%. Regarding short-term risk, IHE is more volatile compared to AFMBX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AFMBX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, ABALX has a market cap of 291.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while ABALX trades at $41.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas ABALX's P/E ratio is 26.59. In terms of profitability, IHE's ROE is +0.00%, compared to ABALX's ROE of +0.13%. Regarding short-term risk, IHE is more volatile compared to ABALX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check ABALX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, CLBAX has a market cap of 287.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while CLBAX trades at $40.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas CLBAX's P/E ratio is 26.66. In terms of profitability, IHE's ROE is +0.00%, compared to CLBAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to CLBAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check CLBAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AMBFX has a market cap of 286.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AMBFX trades at $41.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AMBFX's P/E ratio is 26.60. In terms of profitability, IHE's ROE is +0.00%, compared to AMBFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AMBFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AMBFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RLBGX has a market cap of 286.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RLBGX trades at $41.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RLBGX's P/E ratio is 26.60. In terms of profitability, IHE's ROE is +0.00%, compared to RLBGX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RLBGX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RLBGX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RGABX has a market cap of 269.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RGABX trades at $76.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RGABX's P/E ratio is 32.14. In terms of profitability, IHE's ROE is +0.00%, compared to RGABX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RGABX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RGABX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RGAAX has a market cap of 264.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RGAAX trades at $75.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RGAAX's P/E ratio is 32.15. In terms of profitability, IHE's ROE is +0.00%, compared to RGAAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RGAAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RGAAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FCTDX has a market cap of 262.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FCTDX trades at $22.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FCTDX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to FCTDX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FCTDX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FCTDX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VTV has a market cap of 261.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VTV trades at $226.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VTV's P/E ratio is 22.39. In terms of profitability, IHE's ROE is +0.00%, compared to VTV's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to VTV. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VTV's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VVIAX has a market cap of 260.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VVIAX trades at $88.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VVIAX's P/E ratio is 22.26. In terms of profitability, IHE's ROE is +0.00%, compared to VVIAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VVIAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VVIAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, GFACX has a market cap of 257.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while GFACX trades at $73.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas GFACX's P/E ratio is 33.03. In terms of profitability, IHE's ROE is +0.00%, compared to GFACX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to GFACX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check GFACX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, SWVXX has a market cap of 245.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while SWVXX trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas SWVXX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to SWVXX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to SWVXX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check SWVXX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, PIMIX has a market cap of 231.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while PIMIX trades at $10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas PIMIX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to PIMIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to PIMIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check PIMIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, PONPX has a market cap of 231.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while PONPX trades at $10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas PONPX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to PONPX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to PONPX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check PONPX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VO has a market cap of 229.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VO trades at $82.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VO's P/E ratio is 24.57. In terms of profitability, IHE's ROE is +0.00%, compared to VO's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to VO. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VO's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VMCPX has a market cap of 228.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VMCPX trades at $447.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VMCPX's P/E ratio is 24.43. In terms of profitability, IHE's ROE is +0.00%, compared to VMCPX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VMCPX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VMCPX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VIMAX has a market cap of 228.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VIMAX trades at $411.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VIMAX's P/E ratio is 24.43. In terms of profitability, IHE's ROE is +0.00%, compared to VIMAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VIMAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VIMAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VMCIX has a market cap of 228.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VMCIX trades at $90.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VMCIX's P/E ratio is 24.43. In terms of profitability, IHE's ROE is +0.00%, compared to VMCIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VMCIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VMCIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, ODIDX has a market cap of 213.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while ODIDX trades at $8.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas ODIDX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to ODIDX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to ODIDX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check ODIDX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VB has a market cap of 194.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VB trades at $304.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VB's P/E ratio is 22.29. In terms of profitability, IHE's ROE is +0.00%, compared to VB's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to VB. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VB's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VSCIX has a market cap of 193.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VSCIX trades at $146.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VSCIX's P/E ratio is 22.13. In terms of profitability, IHE's ROE is +0.00%, compared to VSCIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VSCIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VSCIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VSMAX has a market cap of 193.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VSMAX trades at $146.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VSMAX's P/E ratio is 22.13. In terms of profitability, IHE's ROE is +0.00%, compared to VSMAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VSMAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VSMAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, APO-PA has a market cap of 190.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while APO-PA trades at $170.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas APO-PA's P/E ratio is 20.43. In terms of profitability, IHE's ROE is +0.00%, compared to APO-PA's ROE of +0.09%. Regarding short-term risk, IHE is more volatile compared to APO-PA. This indicates higher risk in terms of short-term price fluctuations for IHE.Check APO-PA's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RICBX has a market cap of 185.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RICBX trades at $68.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RICBX's P/E ratio is 28.64. In terms of profitability, IHE's ROE is +0.00%, compared to RICBX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RICBX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RICBX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AICCX has a market cap of 185.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AICCX trades at $67.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AICCX's P/E ratio is 28.64. In terms of profitability, IHE's ROE is +0.00%, compared to AICCX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AICCX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AICCX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FCNKX has a market cap of 185B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FCNKX trades at $26.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FCNKX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to FCNKX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FCNKX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FCNKX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FCNTX has a market cap of 185B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FCNTX trades at $26.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FCNTX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to FCNTX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FCNTX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FCNTX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FUNFX has a market cap of 182.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FUNFX trades at $103.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FUNFX's P/E ratio is 28.88. In terms of profitability, IHE's ROE is +0.00%, compared to FUNFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FUNFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FUNFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FINFX has a market cap of 182.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FINFX trades at $103.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FINFX's P/E ratio is 28.87. In terms of profitability, IHE's ROE is +0.00%, compared to FINFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FINFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FINFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, ANCFX has a market cap of 182.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while ANCFX trades at $103.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas ANCFX's P/E ratio is 28.87. In terms of profitability, IHE's ROE is +0.00%, compared to ANCFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to ANCFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check ANCFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, CICAX has a market cap of 181.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while CICAX trades at $68.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas CICAX's P/E ratio is 28.88. In terms of profitability, IHE's ROE is +0.00%, compared to CICAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to CICAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check CICAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FFICX has a market cap of 180.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FFICX trades at $69.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FFICX's P/E ratio is 28.69. In terms of profitability, IHE's ROE is +0.00%, compared to FFICX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FFICX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FFICX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AICFX has a market cap of 180.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AICFX trades at $68.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AICFX's P/E ratio is 28.67. In terms of profitability, IHE's ROE is +0.00%, compared to AICFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AICFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AICFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AIVSX has a market cap of 180.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AIVSX trades at $69.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AIVSX's P/E ratio is 28.68. In terms of profitability, IHE's ROE is +0.00%, compared to AIVSX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AIVSX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AIVSX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RICAX has a market cap of 180.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RICAX trades at $68.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RICAX's P/E ratio is 28.64. In terms of profitability, IHE's ROE is +0.00%, compared to RICAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RICAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RICAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, BLK has a market cap of 179.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while BLK trades at $1,156.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas BLK's P/E ratio is 22.60. In terms of profitability, IHE's ROE is +0.00%, compared to BLK's ROE of +0.12%. Regarding short-term risk, IHE is more volatile compared to BLK. This indicates higher risk in terms of short-term price fluctuations for IHE.Check BLK's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, CFNAX has a market cap of 178.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while CFNAX trades at $103.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas CFNAX's P/E ratio is 28.91. In terms of profitability, IHE's ROE is +0.00%, compared to CFNAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to CFNAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check CFNAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AFIFX has a market cap of 178B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AFIFX trades at $103.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AFIFX's P/E ratio is 28.86. In terms of profitability, IHE's ROE is +0.00%, compared to AFIFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AFIFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AFIFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RFNCX has a market cap of 178B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RFNCX trades at $103.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RFNCX's P/E ratio is 28.85. In terms of profitability, IHE's ROE is +0.00%, compared to RFNCX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RFNCX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RFNCX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FNPFX has a market cap of 173.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FNPFX trades at $76.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FNPFX's P/E ratio is 27.33. In terms of profitability, IHE's ROE is +0.00%, compared to FNPFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FNPFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FNPFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, NPFFX has a market cap of 173.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while NPFFX trades at $75.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas NPFFX's P/E ratio is 27.30. In terms of profitability, IHE's ROE is +0.00%, compared to NPFFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to NPFFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check NPFFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, BX has a market cap of 170.8B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while BX trades at $143.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas BX's P/E ratio is 24.21. In terms of profitability, IHE's ROE is +0.00%, compared to BX's ROE of +0.41%. Regarding short-term risk, IHE is less volatile compared to BX. This indicates lower risk in terms of short-term price fluctuations for IHE.Check BX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RNPGX has a market cap of 169.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RNPGX trades at $76.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RNPGX's P/E ratio is 27.33. In terms of profitability, IHE's ROE is +0.00%, compared to RNPGX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RNPGX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RNPGX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, ANWPX has a market cap of 169.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while ANWPX trades at $76.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas ANWPX's P/E ratio is 27.31. In terms of profitability, IHE's ROE is +0.00%, compared to ANWPX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to ANWPX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check ANWPX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RNPCX has a market cap of 169.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RNPCX trades at $73.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RNPCX's P/E ratio is 27.27. In terms of profitability, IHE's ROE is +0.00%, compared to RNPCX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RNPCX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RNPCX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, SPCK has a market cap of 168B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while SPCK trades at $22.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas SPCK's P/E ratio is -20.16. In terms of profitability, IHE's ROE is +0.00%, compared to SPCK's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to SPCK. This indicates higher risk in terms of short-term price fluctuations for IHE.Check SPCK's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VEMRX has a market cap of 166.9B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VEMRX trades at $126.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VEMRX's P/E ratio is 16.88. In terms of profitability, IHE's ROE is +0.00%, compared to VEMRX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VEMRX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VEMRX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VEMAX has a market cap of 165.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VEMAX trades at $50.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VEMAX's P/E ratio is 16.88. In terms of profitability, IHE's ROE is +0.00%, compared to VEMAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VEMAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VEMAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, WGIFX has a market cap of 157.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while WGIFX trades at $82.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas WGIFX's P/E ratio is 25.44. In terms of profitability, IHE's ROE is +0.00%, compared to WGIFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to WGIFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check WGIFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FPMAX has a market cap of 154.3B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FPMAX trades at $10.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FPMAX's P/E ratio is N/A. In terms of profitability, IHE's ROE is +0.00%, compared to FPMAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FPMAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FPMAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AWSHX has a market cap of 154.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AWSHX trades at $69.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AWSHX's P/E ratio is 26.58. In terms of profitability, IHE's ROE is +0.00%, compared to AWSHX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AWSHX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AWSHX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RWMFX has a market cap of 154.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RWMFX trades at $68.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RWMFX's P/E ratio is 26.59. In terms of profitability, IHE's ROE is +0.00%, compared to RWMFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RWMFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RWMFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FWMIX has a market cap of 154.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FWMIX trades at $68.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FWMIX's P/E ratio is 26.59. In terms of profitability, IHE's ROE is +0.00%, compared to FWMIX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FWMIX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FWMIX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, CWMAX has a market cap of 153.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while CWMAX trades at $68.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas CWMAX's P/E ratio is 26.58. In terms of profitability, IHE's ROE is +0.00%, compared to CWMAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to CWMAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check CWMAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, WSHFX has a market cap of 153.2B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while WSHFX trades at $68.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas WSHFX's P/E ratio is 26.57. In terms of profitability, IHE's ROE is +0.00%, compared to WSHFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to WSHFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check WSHFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, WSHCX has a market cap of 150.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while WSHCX trades at $67.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas WSHCX's P/E ratio is 26.53. In terms of profitability, IHE's ROE is +0.00%, compared to WSHCX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to WSHCX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check WSHCX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RWMBX has a market cap of 150.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RWMBX trades at $67.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RWMBX's P/E ratio is 26.52. In terms of profitability, IHE's ROE is +0.00%, compared to RWMBX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RWMBX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RWMBX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, GLD has a market cap of 149.4B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while GLD trades at $423.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas GLD's P/E ratio is 232664.84. In terms of profitability, IHE's ROE is +0.00%, compared to GLD's ROE of +0.00%. Regarding short-term risk, IHE is more volatile compared to GLD. This indicates higher risk in terms of short-term price fluctuations for IHE.Check GLD's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, SWPPX has a market cap of 147.1B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while SWPPX trades at $19.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas SWPPX's P/E ratio is 27.38. In terms of profitability, IHE's ROE is +0.00%, compared to SWPPX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to SWPPX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check SWPPX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, FIFAX has a market cap of 146.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while FIFAX trades at $28.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas FIFAX's P/E ratio is 20.00. In terms of profitability, IHE's ROE is +0.00%, compared to FIFAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to FIFAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check FIFAX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RERGX has a market cap of 144.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RERGX trades at $65.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RERGX's P/E ratio is 19.72. In terms of profitability, IHE's ROE is +0.00%, compared to RERGX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RERGX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RERGX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AEGFX has a market cap of 144.5B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AEGFX trades at $64.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AEGFX's P/E ratio is 19.68. In terms of profitability, IHE's ROE is +0.00%, compared to AEGFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AEGFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AEGFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, RERHX has a market cap of 142.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while RERHX trades at $64.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas RERHX's P/E ratio is 19.69. In terms of profitability, IHE's ROE is +0.00%, compared to RERHX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to RERHX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check RERHX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AEPFX has a market cap of 142.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AEPFX trades at $65.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AEPFX's P/E ratio is 19.71. In terms of profitability, IHE's ROE is +0.00%, compared to AEPFX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AEPFX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AEPFX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, AEPGX has a market cap of 142.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while AEPGX trades at $65.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas AEPGX's P/E ratio is 19.69. In terms of profitability, IHE's ROE is +0.00%, compared to AEPGX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to AEPGX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check AEPGX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, NAESX has a market cap of 139.7B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while NAESX trades at $146.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas NAESX's P/E ratio is 22.13. In terms of profitability, IHE's ROE is +0.00%, compared to NAESX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to NAESX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check NAESX's competition here

iShares U.S. Pharmaceuticals ETF (AMEX: IHE) plays a significant role within the Financial Services sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IHE stands at 1.2B. In comparison, VITAX has a market cap of 139.6B. Regarding current trading prices, IHE is priced at $106.79 on the AMEX, while VITAX trades at $485.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IHE currently has a P/E ratio of 29.91, whereas VITAX's P/E ratio is 35.55. In terms of profitability, IHE's ROE is +0.00%, compared to VITAX's ROE of N/A. Regarding short-term risk, IHE is more volatile compared to VITAX. This indicates higher risk in terms of short-term price fluctuations for IHE.Check VITAX's competition here